T. Rowe Price Investment Management
CAI

T. Rowe Price Investment Management’s Caris Life Sciences CAI Stock Holding History

T. Rowe Price Investment Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.5M Sell
5,079,141
-509,116
-9% -$9.11M 0.06% 288
2026
Q1 		$99.9M Sell
5,588,257
-3,617,702
-39% -$79.1M 0.07% 248
2025
Q4 		$248M Buy
9,205,959
+1,180,200
+15% +$33.2M 0.16% 148
2025
Q3 		$243M Buy
8,025,759
+721,772
+10% +$23M 0.15% 153
2025
Q2 		$195M Buy
+7,303,987
New +$197M 0.12% 180

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management's CAI Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Caris Life Sciences (CAI) stake by 9.1% in Q2 2026, selling an estimated $9.11M and leaving 5,079,141 shares worth $90.5M. The position accounts for 0.06% of the portfolio, ranked #288.

T. Rowe Price Investment Management first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $248M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • T. Rowe Price Investment Management held 5,079,141 shares of Caris Life Sciences worth $90.5M as of Q2 2026.
  • T. Rowe Price Investment Management sold 509,116 Caris Life Sciences shares in Q2 2026, an estimated $9.11M.
  • Caris Life Sciences made up 0.06% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #288 holding.
  • T. Rowe Price Investment Management first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • T. Rowe Price Investment Management's Caris Life Sciences position peaked at $248M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.